Neuro-Bio Gets $3.2M in Funding from U.S. Investor to Develop New Approach to Alzheimer’s

Neuro-Bio Gets $3.2M in Funding from U.S. Investor to Develop New Approach to Alzheimer’s
British pharmaceutical company Neuro-Bio has received $3.2 million in financing from Los Angeles-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s disease. This tool stems from a novel approach to Alzheimer’s pioneered in 2013 by Neuro-Bio’s founder and CEO, Susan Greenfield, and her team at Oxford University. Resulting from 40 years of basic research, this approach

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *